52 research outputs found
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Traditionally, the major objective in phase I trials is to identify a
working-dose for subsequent studies, whereas the major endpoint in phase II and
III trials is treatment efficacy. The dose sought is typically referred to as
the maximum tolerated dose (MTD). Several statistical methodologies have been
proposed to select the MTD in cancer phase I trials. In this manuscript, we
focus on a Bayesian adaptive design, known as escalation with overdose control
(EWOC). Several aspects of this design are discussed, including large sample
properties of the sequence of doses selected in the trial, choice of prior
distributions, and use of covariates. The methodology is exemplified with
real-life examples of cancer phase I trials. In particular, we show in the
recently completed ABR-217620 (naptumomab estafenatox) trial that omitting an
important predictor of toxicity when dose assignments to cancer patients are
determined results in a high percent of patients experiencing severe side
effects and a significant proportion treated at sub-optimal doses.Comment: Published in at http://dx.doi.org/10.1214/10-STS333 the Statistical
Science (http://www.imstat.org/sts/) by the Institute of Mathematical
Statistics (http://www.imstat.org
A Neutrosophic Description Logic
Description Logics (DLs) are appropriate, widely used, logics for managing
structured knowledge. They allow reasoning about individuals and concepts, i.e.
set of individuals with common properties. Typically, DLs are limited to
dealing with crisp, well defined concepts. That is, concepts for which the
problem whether an individual is an instance of it is yes/no question. More
often than not, the concepts encountered in the real world do not have a
precisely defined criteria of membership: we may say that an individual is an
instance of a concept only to a certain degree, depending on the individual's
properties. The DLs that deal with such fuzzy concepts are called fuzzy DLs. In
order to deal with fuzzy, incomplete, indeterminate and inconsistent concepts,
we need to extend the fuzzy DLs, combining the neutrosophic logic with a
classical DL. In particular, concepts become neutrosophic (here neutrosophic
means fuzzy, incomplete, indeterminate, and inconsistent), thus reasoning about
neutrosophic concepts is supported. We'll define its syntax, its semantics, and
describe its properties.Comment: 18 pages. Presented at the IEEE International Conference on Granular
Computing, Georgia State University, Atlanta, USA, May 200
Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control
We describe a design for cancer phase I clinical trials that takes into account patients heterogeneity thought to be related to treatment susceptibility. The goal is to estimate the maximum tolerated dose (MTD) given patient’s specific dichotomous covariate value. The design is Bayesian adaptive and is an extension of escalation with overdose control (EWOC). We will assess the performance of this method by comparing the following designs via extensive simulations: (1) design using a covariate; patients are accrued to the trial sequentially and the dose given to a patient depends on his/her baseline covariate value, (2) design ignoring the covariate; patients are accrued to the trial sequentially and the dose given to a patient does not depend on his/her baseline covariate value, and (3) design using separate trials; in each group, patients are accrued to the trial sequentially and EWOC is implemented in each group. These designs are compared with respect to safety of the trial and efficiency of the estimates of the MTDs via extensive simulations. We found that ignoring a significant baseline binary covariate in the model results in a substantial number of patients being overdosed. On the other hand, accounting for a nonsignificant covariate in the model has practically no effect on the safety of the trial and efficiency of the estimates of the MTDs
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
AimsThe mechanistic basis of the symptoms and signs of myocardial ischaemia in patients without obstructive coronary artery disease (CAD) and evidence of coronary microvascular dysfunction (CMD) is unclear. The aim of this study was to mechanistically test short-term late sodium current inhibition (ranolazine) in such subjects on angina, myocardial perfusion reserve index, and diastolic filling.Materials and resultsRandomized, double-blind, placebo-controlled, crossover, mechanistic trial in subjects with evidence of CMD [invasive coronary reactivity testing or non-invasive cardiac magnetic resonance imaging myocardial perfusion reserve index (MPRI)]. Short-term oral ranolazine 500-1000 mg twice daily for 2 weeks vs. placebo. Angina measured by Seattle Angina Questionnaire (SAQ) and SAQ-7 (co-primaries), diary angina (secondary), stress MPRI, diastolic filling, quality of life (QoL). Of 128 (96% women) subjects, no treatment differences in the outcomes were observed. Peak heart rate was lower during pharmacological stress during ranolazine (-3.55 b.p.m., P < 0.001). The change in SAQ-7 directly correlated with the change in MPRI (correlation 0.25, P = 0.005). The change in MPRI predicted the change in SAQ QoL, adjusted for body mass index (BMI), prior myocardial infarction, and site (P = 0.0032). Low coronary flow reserve (CFR <2.5) subjects improved MPRI (P < 0.0137), SAQ angina frequency (P = 0.027), and SAQ-7 (P = 0.041).ConclusionsIn this mechanistic trial among symptomatic subjects, no obstructive CAD, short-term late sodium current inhibition was not generally effective for SAQ angina. Angina and myocardial perfusion reserve changes were related, supporting the notion that strategies to improve ischaemia should be tested in these subjects.Trial registrationclinicaltrials.gov Identifier: NCT01342029
caGrid-Enabled caBIGTM Silver Level Compatible Head and Neck Cancer Tissue Database System
There are huge amounts of biomedical data generated by research labs in each cancer institution. The data are stored in various formats and accessed through numerous interfaces. It is very difficult to exchange and integrate the data among different cancer institutions, even among different research labs within the same institution, in order to discover useful biomedical knowledge for the healthcare community. In this paper, we present the design and implementation of a caGrid-enabled caBIGTM silver level compatible head and neck cancer tissue database system. The system is implemented using a set of open source software and tools developed by the NCI, such as the caCORE SDK and caGrid. The head and neck cancer tissue database system has four interfaces: Web-based, Java API, XML utility, and Web service. The system has been shown to provide robust and programmatically accessible biomedical information services that syntactically and semantically interoperate with other resources
Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
The main objective of cancer phase I clinical trials is to determine a maximum tolerated dose (MTD) of a new experimental treatment. In practice, most of these trials are designed so that three patients per cohort are treated at the same dose level. In this paper, we compare the safety and efficiency of trials using the escalation with overdose control (EWOC) scheme designed with three or only one patient per cohort. We show through simulations that the number of patients per cohort does not impact the proportion of patients given therapeutic doses, safety of the trial, and efficiency of the estimate of the MTD. Additionally, we present guidelines and tabulated values on the number of patients needed to design a phase I cancer clinical trial using EWOC to achieve a given accuracy of the estimate of the MTD
Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
Escalation with overdose control (EWOC) is a Bayesian adaptive phase I clinical trial design that produces consistent sequences of doses while controlling the probability that patients are overdosed. However, this design does not take explicitly into account the time it takes for a patient to exhibit dose limiting toxicity (DLT) since the occurrence of DLT is ascertained within a predetermined window of time. Models to estimate the Maximum Tolerated Dose (MTD) that use the exact time when the DLT occurs are expected to be more precise than those where the variable of interest is categorized as presence or absence of DLT, given that information is lost in the process of categorization of the variable. We develop a class of parametric models for time to toxicity data in order to estimate the MTD efficiently, and present extensive simulations showing that the method has good design operating characteristics relative to the original EWOC and a version of time to event EWOC (TITE-EWOC) which allocates weights to account for the time it takes for a patient to exhibit DLT. The methodology is exemplified by a cancer phase I clinical trial we designed in order to estimate the MTD of Veliparib (ABT-888) in combination with fixed doses of gemcitabine and intensity modulated radiation therapy in patients with locally advanced, un-resectable pancreatic cancer
Comparison between continuous and discrete doses for model based designs in cancer dose finding.
Despite of an extensive statistical literature showing that discretizing continuous variables results in substantial loss of information, categorization of continuous variables has been a common practice in clinical research and in cancer dose finding (phase I) clinical trials. The objective of this study is to quantify the loss of information incurred by using a discrete set of doses to estimate the maximum tolerated dose (MTD) in phase I trials, instead of a continuous dose support. Escalation With Overdose Control and Continuous Reassessment Method were used because they are model-based designs where dose can be specified either as continuous or as a set of discrete levels. Five equally spaced sets of doses with different interval lengths and three sample sizes with sixteen scenarios were evaluated to compare the operating characteristics between continuous and discrete dose designs by Monte Carlo simulation. Loss of information was quantified by safety and efficiency measures. We conclude that if there is insufficient knowledge about the true MTD value, as commonly happens in phase I clinical trials, a continuous dose scheme minimizes information loss. If one is required to implement a design using discrete doses, then a scheme with 9 to 11 doses may yield similar results to the continuous dose scheme
- …